Summary of HR 1082: Shandra Eisenga Human Cell and Tissue Product Safety Act

Purpose and Intent

The Shandra Eisenga Human Cell and Tissue Product Safety Act (HR 1082) aims to enhance public and healthcare provider awareness regarding the risks and benefits associated with human cell and tissue product transplants. This legislation is a response to the tragic death of Shandra Eisenga, who died from complications related to a tuberculosis infection contracted through a contaminated tissue donation. The bill seeks to prevent similar incidents by improving safety protocols and educational outreach.

Key Provisions

• National Education Campaign: The bill mandates the Secretary of Health and Human Services (HHS) to conduct a national, evidence-based education campaign aimed at both the public and healthcare providers. This campaign will focus on the potential risks and benefits of human cell and tissue product transplants.

• FDA Enforcement Authority: The bill grants the Food and Drug Administration (FDA) the authority to impose civil monetary penalties for violations related to donor eligibility and good tissue practices. This aims to ensure compliance with safety standards.

• Public Health Promotion: The FDA will be required to publish educational materials, best practices, and other relevant information on its public website. Additionally, the FDA will conduct workshops and educational sessions for stakeholders involved in tissue donation and transplantation.

• Reporting Requirements: The HHS Secretary will be tasked with reporting to Congress on recommendations for the regulation of human cell and tissue products, ensuring ongoing oversight and improvement in safety measures.

Impact

The legislation is expected to:
- Increase Public Awareness: By educating the public and healthcare providers, the bill aims to foster greater understanding and trust in human cell and tissue products.
- Enhance Patient Safety: Improved regulations and enforcement mechanisms are intended to reduce the risk of infections and complications arising from tissue transplants.
- Support Healthcare Providers: By providing resources and training, the bill will assist healthcare professionals in making informed decisions regarding tissue donations.

Procedural Timeline

• Introduced: February 6, 2025
• House Committee Action: The bill was reported favorably by the Committee on Energy and Commerce on June 12, 2025, and passed in the House on June 23, 2025.
• Senate Action: The bill was received in the Senate on June 24, 2025, where it was read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Conclusion

HR 1082 represents a significant step towards improving the safety and efficacy of human cell and tissue product transplants. By focusing on education, enforcement, and regulatory oversight, the bill aims to prevent future tragedies and enhance the overall safety of tissue donation practices.